Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels...
Guardado en:
Autores principales: | Zdeněk Kejík, Robert Kaplánek, Petr Dytrych, Michal Masařík, Kateřina Veselá, Nikita Abramenko, David Hoskovec, Martina Vašáková, Jarmila Králová, Pavel Martásek, Milan Jakubek |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a9212fe2fd9443cd854b6088bd96b44c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients
por: Verena Lieb, et al.
Publicado: (2021) -
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma
por: Jiang WT, et al.
Publicado: (2018) -
Multifunctional Gold Nano-Cytosensor With Quick Capture, Electrochemical Detection, and Non-Invasive Release of Circulating Tumor Cells for Early Cancer Treatment
por: Rui Zhang, et al.
Publicado: (2021) -
Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine
por: Arechederra María, et al.
Publicado: (2020) -
Preparation and Characterization of Highly Water Soluble Curcumin – Dextrose Cocrystal
por: Katherine Kho, et al.
Publicado: (2018)